TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603). (2025)

Information & Authors

Information

Published In

TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603). (1)

Journal of Clinical Oncology

Volume 38 • Number 15_suppl • May 2020

Pages: 5500

Copyright

© 2020 American Society of Clinical Oncology.

History

Published in print: May 20, 2020

Published online: May 25, 2020

Permissions

Request permissions for this article.

Authors

Affiliations

Michael S Hofman

Peter MacCallum Cancer Centre, Melbourne, Australia;

View all articles by this author

Louise Emmett

Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, Australia;

View all articles by this author

Shahneen Kaur Sandhu

Peter MacCallum Cancer Centre, Melbourne, Australia;

View all articles by this author

Amir Iravani

Peter MacCallum Cancer Centre, Melbourne, Australia;

View all articles by this author

Jeffrey C. Goh

Royal Brisbane and Women's Hospital, Herston, Australia;

View all articles by this author

David A. Pattison

Royal Brisbane and Women’s Hospital, Brisbane, Australia;

View all articles by this author

Thean Hsiang Tan

Royal Adelaide Hospital, Adelaide, Australia;

View all articles by this author

Ian D. Kirkwood

Royal Adelaide Hospital, Adelaide, Australia;

View all articles by this author

Siobhan Ng

Sir Charles Gairdner Hospital, Perth, Australia;

View all articles by this author

Roslyn J. Francis

Sir Charles Gairdner Hospital, Perth, Australia;

View all articles by this author

Natalie K. Rutherford

Calvary Mater Newcastle, Newcastle, Australia;

View all articles by this author

Alison Yan Zhang

NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia;

View all articles by this author

Margaret Mary McJannett

Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Camperdown, NSW, Australia;

View all articles by this author

Martin R. Stockler

NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia;

View all articles by this author

John A. Violet

Peter MacCallum Cancer Centre, Melbourne, Australia;

View all articles by this author

Scott Williams

Peter MacCallum Cancer Centre, Melbourne, Australia;

View all articles by this author

Andrew James Martin

NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia;

View all articles by this author

Ian D. Davis

Monash University Eastern Health Clinical School, Victoria, Australia;

View all articles by this author

Notes

Funding Information

None

Metrics & Citations

Metrics

Altmetric

Citations

Article Citation

  • Michael S Hofman et al.

TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603)..JCO38,5500-5500(2020).

Download Citation

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.


Download article citation data for:

TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).

Michael S Hofman, Louise Emmett, Shahneen Kaur Sandhu, Amir Iravani, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian D. Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie K. Rutherford, Alison Yan Zhang, Margaret Mary McJannett, Martin R. Stockler, John A. Violet, Scott Williams, Andrew James Martin, Ian D. Davis
Journal of Clinical Oncology 2020 38:15_suppl, 5500-5500

View Options

View options

Login options

Check and see if you have full access through your login credentials or institution. ASCO membership or a journal subscription may be required to download the PDF version of this article.

Personal login Institutional Login

Save for later Item saved, go to cart

Purchase Options

Purchase full access to this article.

Purchase this Article

Subscribe

Become an ASCO Member
Renew your ASCO Membership
Subscribe

TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603). (2025)

References

Top Articles
Latest Posts
Recommended Articles
Article information

Author: Mr. See Jast

Last Updated:

Views: 6149

Rating: 4.4 / 5 (75 voted)

Reviews: 90% of readers found this page helpful

Author information

Name: Mr. See Jast

Birthday: 1999-07-30

Address: 8409 Megan Mountain, New Mathew, MT 44997-8193

Phone: +5023589614038

Job: Chief Executive

Hobby: Leather crafting, Flag Football, Candle making, Flying, Poi, Gunsmithing, Swimming

Introduction: My name is Mr. See Jast, I am a open, jolly, gorgeous, courageous, inexpensive, friendly, homely person who loves writing and wants to share my knowledge and understanding with you.